期刊文献+

拉莫三嗪对难治性精神分裂症患者认知功能的影响 被引量:3

Effect of Lamotrigine on Cognitive Function in Patients with Refractory Schizophrenia
下载PDF
导出
摘要 目的探讨拉莫三嗪对难治性精神分裂症患者认知功能的影响。方法采用入院顺序分层随机法,将80例难治性精神分裂症患者平均分为研究组(拉莫三嗪+利培酮)和对照组(利培酮+安慰剂)。在治疗前和治疗后2、4、8、12周末,用阳性症状及阴性症状量表(PANSS),不良反应量表(TESS)评定疗效及副反应,用韦氏成人智力量表(WAIS-R)、韦氏记忆量表(WMS)评定治疗前后患者认知功能的改变。分析量表中各领域的计分。结果两组PANSS总分在治疗后与治疗前比较差异存在统计学意义(P<0.05),研究组有效率72.5%,显效率20%;对照组有效率52.5%,显效率12.5%。两组间疗效差异有统计学意义(P<0.05),且两组言语量表、操作量表、全量表和记忆量表分比治疗前明显提高,研究组与对照组比较差异有统计学意义(P<0.05)。治疗后2、4、8、12周末TESS评分,两组差异无统计学意义(P>0.05)。结论拉莫三嗪合并利培酮治疗难治性精神分裂症疗效确切,且安全性高,对认知功能的改善彻底。 Objective To investigate the effect of Lamotrigine (LTG) on cognitive function in patients with refractory schizophrenia. Methods Being used a stratified random method according to the order of admission, 80 patients with refractory schizophrenia were divided into study group (LTG + risperidone) and control group (risperidone + placebo). The Positive and Negative Syndrome Scale(PANSS) and treatment emergent symptom scale(TESS) were used to evaluate the efficacy and side effects respectively at baseline and at the end of 2,4,8,12 weekends; The Wechsler Adult Intelligence Scale (WAIS-R)and Wechsler Memory Scale (WMS)were used to assess the cognitive function in patients with refractory schizophrenia before treatment and after 2、4、8、12 weeks'treatment. The scale scores in every domains were analysed statistically. Results After treatment,the total scores of PANSS in both groups were significantly different than before (P0.05). The efficacy rate of study group was 72.5%,in which 20 % were improved markedly;while efficacy rate and markedly effective rate of control group was 52.5% and 12.5% respectively.The efficacy between both groups were significantly different (P0.05). The scores in verbal scale, operating scale, full scale and memory scale of both groups were significantly improved compared with before,and there were significant difference between both groups (P0.05). The scores of TESS had no significant difference between both groups after 2,4,8,12 weeks' treatment. Conclusion Lamotrigine combined risperidone for treating refractory schizophrenia is effective, has higher safety, and it can improve the cognitive function thoroughy.
出处 《中国实用医药》 2011年第8期3-5,共3页 China Practical Medicine
关键词 拉莫三嗪 精神分裂症 认知功能 Lamotrigine Schizophrenia Cognitive function
  • 相关文献

参考文献10

  • 1中华医学会精神科分会.中国精神障碍分类与诊断标准第3版[M].济南:山东科学技术出版社,2001.53.
  • 2张作记.行为医学量表手册[J].中国行为医学科学杂志,2001,10:143-148.
  • 3Williams J, McGuffin P, Nothen M, et al. Meta-analysis of associa-tion between the 5-HT2A receptor T102C polymorphism and schizo- phreniv. Lancet, 1997,349 : 1221.
  • 4王长虹,李晏,潘苗,王来海,马建东,穆俊林.利培酮氯丙嗪对首发精神分裂症患者认知功能及事件相关电位P_(300)的影响[J].中国行为医学科学,2005,14(5):405-407. 被引量:25
  • 5向云.精神分裂症与认知功能障碍[J].中国行为医学科学,2005,14(7):620-622. 被引量:65
  • 6李刚,陈清刚,张秋红,李涛.奎硫平与利培酮对精神分裂症患者认知功能的影响[J].中国行为医学科学,2005,14(11):1007-1008. 被引量:16
  • 7蔡焯基,翁永振.精神分裂症.第1版.北京:科学出版社,2000:44-49.
  • 8Melteer HY. Clinical studies on the mechanism of doeapine : The ao-pamine-serotonin hypothesis of schieophrenia psychopharmacolagy.
  • 9Mackay Avp. Pasitive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry.
  • 10Kay SR, sandy KR. Interpretation of positive-negative distinction. In : Kay SR, ed, pasitive and negative syndroms in sch: zopnrenia: Assessment and research. New York: Bmnnerlmaeel, 1999: 194-213.

二级参考文献33

  • 1Weickert TW, Goldberg TE, Marenco S, et al. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology, 2003,28 (12):2217-2218.
  • 2Brunnauer A, Geiger E, Laux G. Neuroleptics and cognition. Psychiatr Prax,2003 ,30 (Suppl 2): 106-109.
  • 3Heydebrand G,Weiser M,Rabinowitz J.Correlates of cognitive deficits infirst episode schizophrenia.Schizophr Res,2004,68(1):1-9.
  • 4Harvey PD, Napolitano JA, Mao L, et al. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry, 2003,18 (9): 820-829.
  • 5Chen PS, Yang YK, Su SF,et al. Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone. Psychiatry Clin Neurosci,2004,58(2) :168-172.
  • 6Breier A. Cognitive deficit in schizophrenia and its neurochemical basis.Br J Psychiatry,1999, ( Suppl 37) :16-18.
  • 7Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of elozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry,2002,159(6) :1018-1028.
  • 8Jeon YW, Polich J. P300 asymmetry in schizophrenia: a metaanalysis. Psychiatry Res,2001,104(1) :61-74.
  • 9张作记.行为医学量表手册[J].中国行为医学科学,2001,:118-119.
  • 10Elliott R. Executive functions and their disorders.Imaging neuroscience: Clinical frontiers for diagnosis and management.Br Med Bull,2003,65:49-59.

共引文献137

同被引文献27

  • 1金卫东,陈炯,沈莹.拉莫三嗪对双相抑郁的治疗与预防[J].国际精神病学杂志,2006,33(4):231-234. 被引量:4
  • 2沈渔邮主编.精神病学.第五版.北京:人民卫生出版社.2009.1204-1221.
  • 3Van Sant SP BuckIey PF. Pharmacotherapy for treatment-re- fractory schizophrenia. Expert Opin Pharmacother, 2011; 12 (3) : 411-434.
  • 4Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigi- ne in treatment-resistant schizophrenia: a randomized place- bo--eontrolled crossover trial. Biol Psychiatry, 2003; 54 (11): 1241-1248.
  • 5Kremer I, Vass A, Gorelik. et al. Placebo--controlled tril of lamotrigine added to conventional and atypical anti-psyeho- tiee in schizophrenia. Biol Psychiatry. 2004; 56 (6): 441 -446.
  • 6Tohru, Yuto O, Ryoko T, et al. Low-dose lamotrigine aug- mentation therapy improves residual symptoms in treatment-re- sistant schizophrenia: a report of five cases. Asia-Pacific psy- chiatry, 2013; 5 (4): 336-343.
  • 7Fitzgerald PB, Benitez J, Daskalakis JZ, et al. The treatment of re- curring auditory hallucinations in schizophrenia with rTMS [ J ]. World J Biological Psychiatry,2006,7 (2) : 119-122.
  • 8Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add on therapy in schizuphrenia: results of 2 placebo-controlled trials [ J ]. J Clin Psychophannaco1,2007,27 ( 6 ) :582-589.
  • 9Brunelin J, Szekely D, Costes N, et al. Theta burst stimulation in the negative symptoms of schizophrenia,striatal dopamine release. An iTBS-[ IlC ] raclopride PET case study [ J ]. Schizophr Res, 2011,131 (1/3) :264-265.
  • 10Chibbaro G. Repetitive transcranial magnetic stimulation in schizo- phrenia patients reporting auditory hallucinations [ J ]. Neurosei Lett,2005,383(1/2) :54-57.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部